John J. Alam, CEO, President, and a director of CervoMed Inc. (NASDAQ:CRVO), filed a Form 4 on November 19, 2026, disclosing two open-market purchases of CervoMed common stock on November 18, 2026.

Key Highlights

  • First transaction: 23,681 shares of common stock acquired at $1.514 per share on November 18, 2026.
  • Second transaction: 76,319 shares of common stock acquired at $1.53 per share on November 18, 2026, also an open-market purchase.
  • Post-transaction direct ownership: 1,584,078 shares of common stock beneficially owned directly following both transactions.
  • Joint holdings included: The direct beneficial ownership figure includes 1,471,578 shares held jointly with his spouse, Dr. Sylvie Gregoire, PharmD., a member of the issuer's Board of Directors.
  • Additional indirect holdings: 12,500 shares held indirectly through the Sylvie Gregoire Roth IRA are reported separately.
  • Multiple roles: Alam is identified in the filing as a Director, a 10% Owner, and an Officer (CEO and President) of CervoMed Inc.

John Alam's November 2026 Open-Market Purchases of CervoMed Stock

According to the filing, John J. Alam executed two separate open-market purchase transactions in CervoMed Inc. common stock on November 18, 2026. The first transaction involved 23,681 shares acquired at a price of $1.514 per share, and the second involved 76,319 shares acquired at $1.53 per share. Both transactions are described in the filing as open-market purchases under transaction code "P."

Following both purchases, the filing reports that Alam's direct beneficial ownership stood at 1,584,078 shares. The filing notes that this figure includes 1,471,578 shares held jointly by Alam and his spouse, Dr. Sylvie Gregoire, PharmD., who is identified as a member of the issuer's Board of Directors, as well as 112,500 shares held by the John J. Alam Roth IRA. Separately, 12,500 shares held by the Sylvie Gregoire Roth IRA are reported as an indirect holding.

CervoMed Inc. is the issuer, listed on NASDAQ under the ticker symbol CRVO. Alam holds multiple relationships to the issuer as disclosed in this filing, serving simultaneously as CEO and President, a Director, and a 10% Owner. The filing was signed by John Alam and dated November 19, 2026.

What Was Disclosed

The filing disclosed two open-market purchases of CervoMed common stock by CEO and President John J. Alam on November 18, 2026, at prices of $1.514 and $1.53 per share, with direct beneficial ownership reported at 1,584,078 shares following the transactions.